Newsroom

Vigilant Biosciences CEO, Matthew H.J. Kim, is Honored by BioFlorida with Weaver H. Gaines Entrepreneur of the Year Award 10.15.15

FORT LAUDERDALE, Fla., Oct. 13, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that BioFlorida has awarded Vigilant's founder and CEO, Matthew H.J. Kim, the...

Vigilant Biosciences, Inc. Expands Leadership Team, Appoints James P. Mc Menamy as Vice President, Commercialization 10.6.15

FORT LAUDERDALE, Fla., Oct. 5, 2015 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the appointment of James P. Mc Menamy as Vice President, Commercialization. In this...

Florida Institute Receives Economic Development Award 10.6.15

Gainesville and Boca Raton, FL., Oct. 6, 2015 -- The Florida Institute for the Commercialization of Public Research (the Institute) announced today that it received the 2015 Distinguished Organization Award from the Research Park at Florida Atlantic University. Select individuals and organizations...

Biscayne Pharmaceuticals Merges With Insero Health, Adding Clinical-Stage Novel Epilepsy Program And Other CNS Assets 10.5.15

--Insero Scientific Co-founder and Harvard Epilepsy Expert Dr. Steven Schachter Joins Biscayne as Senior Science Advisor----Drug Development Veteran Stephen Collins Is Named CEO and Launches Series B Financing-- MIAMI BEACH, Fla., Oct. 5, 2015 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc., a...

Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program 9.30.15

September 25, 2015  NEW YORK & TAMPA, Fla.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Moffitt Cancer Center today announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy (I-O RPM) program in...

Share

Facebook icon
Twitter icon
LinkedIn icon
Pinterest icon
e-mail icon